Table 2.
Baseline clinical characteristics in Mavacamten treatment group versus placebo group
| EXPLORER-HCM (NCT03470545) [17] | MAVERICK-HCM (NCT03442764) [21] | VALOR-HCM (NCT04349072) [18] | EXPLORER-CN (NCT05174416) [20] | |||||
|---|---|---|---|---|---|---|---|---|
| Mavacamten | Placebo | Mavacamten | Placebo | Mavacamten | Placebo | Mavacamten | Placebo | |
| Age (years) | 58.5 | 58.5 | 54 | 53.8 | 59.8 | 60.9 | 52.4 | 51 |
| Male | 54 | 65 | 47.5 | 31.6 | 51.8 | 50 | 41 | 17 |
| BMI, kg m−2 | 29.7 (4.9) | 29.2 (5.6) | 29.3 (5.2) | 31 (4.9) | 29.3 (4.8) | 31.9 (6.2) | 25.2 (3.5) | 26.1 (3.1) |
| HCM genetic testing perform | 73 | 78 | 70 | 63.2 | – | – | – | – |
| Pathogenic or likely pathogenic HCM gene variant | 31 | 22 | 50 | 66.7 | – | – | – | – |
| Medical history | ||||||||
| Family history of HCM | 27 | 28 | – | – | 30.4 | 26.8 | – | – |
| SRT | 9 | 6 | – | – | – | – | – | – |
| Diabetes mellitus | 5 | 6 | – | – | – | – | – | – |
| Dyslipidemia | 22 | 30 | – | – | – | – | 4 | 0 |
| Hypertension | 46 | 41 | – | – | 64.3 | 60.7 | 3 | 0 |
| Smoking | – | – | – | – | – | – | – | – |
| Obesity | 12 | 11 | – | – | – | – | – | – |
| Coronary artery disease | 10 | 5 | – | – | – | – | – | – |
| ICD | 22 | 23 | – | – | 16.1 | 17.9 | – | – |
| Atrial fibrillation | 10 | 18 | – | – | 19.6 | 14.3 | 2 | 0 |
| Chronic lung disease | 16 | 11 | – | – | – | – | – | – |
| Background HCM therapy | ||||||||
| Beta-blocker | 76 | 74 | 62.5 | 63.2 | 46.4 | 44.6 | 48 | 24 |
| Calcium channel blocker | 20 | 13 | 25 | 15.8 | 12.5 | 17.9 | 4 | 2 |
| NYHA-FC II | 72 | 74 | 82.5 | 68.4 | 7.1 | 7.1 | 44 | 18 |
| NYHC-FC III | 28 | 26 | 17.5 | 31.6 | 92.9 | 92.9 | 10 | 9 |
| pVO2, ml/kg/min | 18.9 (14.9) | 19.9 (4.9) | 20.4 (6) | 17.9 (5.1) | – | – | – | – |
| Echocardiac parameters | ||||||||
| LVEF, % | 74 (6) | 74 (6) | 68.7 (5.5) | 66.4 (7.7) | 67.9 (3.7) | 68.3 (3.2) | 77.8 (6.9) | 77 (6.7) |
| Maximum left ventricular wall thickness, mm | 20 (4) | 20 (3) | 20.6 (4.0) | 18.8 (3.5) | – | – | 22.9 (4.9) | 24.3 (6.4) |
| LVOT gradient, rest, mm Hg | 52 (29) | 51 (32) | – | – | 51.2 (31.4) | 46.3 (30.5) | 74.6 (35.1) | 73.4 (32.2) |
| LVOT gradient, Valsalva, mm Hg | 72 (32) | 74 (32) | – | – | 75.3 (30.8) | 76.2 (29.9) | 106.8 (43.2) | 99.8 (41.1) |
| LVOT gradient post-exercise, mm Hg | 86 (34) | 84 (36) | – | – | 82.5 (34.7) | 85.2 (37) | – | – |
| Left atrial volume index, ml/m2 | 40 (12) | 41 (14) | 37.3 (13) | 40.8 (15.2) | 41.3 (16.5) | 40.9 (15.2) | 43.3 (12.1) | 47.5 (14.7) |
| Left atrial diameter, mm | 42 (5) | 42 (6) | – | – | – | – | – | – |
Data are presented as % or mean (standard deviation)
BMI body mass index, HCM hypertrophic cardiomyopathy, ICD implantable cardioverter defibrillator, LVEF left ventricular ejection fraction, LVOT left ventricular outflow tract, NYHA-FC New York Heart Association functional class, pVO2 peak oxygen consumption, SRT septal reduction therapy, and – no information available